Semaglutide has become a drug of interest for NASH since many studies show a decrease in alanine transaminase (ALT) and high-sensitivity C-reactive protein (hs-CRP) in patients diagnosed with type 2 diabetes and obesity [8]. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.